Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 6/20 | 0.54 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.42 |
| ▸ | KDM1A | O60341 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMYD3 | Q9H7B4 | 4/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1105547 | 0.86 | SMN1; SMN2 (0.45) | MCHR1CHRM4CYP2D6KMT2AOPRK1 | |
| SCHEMBL405132 | 0.85 | CHRM4 (0.43) | MCHR1CHRM4CYP2D6MEN1POLB | |
| SCHEMBL404206 | 0.84 | MCHR1 (0.46) | MCHR1CHRM4CYP2D6KMT2AOPRK1 | |
| SCHEMBL404847 | 0.82 | MCHR1 (0.44) | MCHR1CHRM4CYP2D6MEN1POLB | |
| SCHEMBL4538278 | 0.82 | CHRM4 (0.45) | MCHR1CHRM4CYP2D6MEN1POLB | |
| SCHEMBL1095512 | 0.82 | MCHR1 (0.52) | MCHR1CHRM4CYP2D6HRH3 | |
| SCHEMBL404346 | 0.82 | HDAC6 (0.44) | MCHR1CHRM4KMT2AOPRK1 | |
| SCHEMBL403500 | 0.81 | CD274 (0.48) | MEN1KMT2A | |
| SCHEMBL404085 | 0.81 | HDAC4 (0.44) | MCHR1CYP2D6MEN1POLBKMT2A | |
| SCHEMBL402467 | 0.77 | ALDH1A1 (0.48) | MCHR1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153843-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153843-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153843-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2012-04-10 | — | — | US | disclosed |
| US-8101640-B2 | Antibacterial agents | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101640-B2 | Antibacterial agents | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101640-B2 | Antibacterial agents | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8084615-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2011-12-27 | — | — | US | disclosed |
| US-8084615-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2011-12-27 | — | — | US | disclosed |
| US-8084615-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2011-12-27 | — | — | US | disclosed |
| US-7989660-B2 | BACTERICIDE AGAINST GRAMNEGATIVE BACTERIA; RESPIARATORY SYSTEM DISORDERS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20080269221-A1 | ANTIBACTERIAL AGENTS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080269221-A1 | ANTIBACTERIAL AGENTS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080269221-A1 | ANTIBACTERIAL AGENTS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-7358359-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2008-04-15 | — | — | US | disclosed |
| US-7358359-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2008-04-15 | — | — | US | disclosed |
| US-7358359-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2008-04-15 | — | — | US | disclosed |
| US-20070244197-A1 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244197-A1 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244197-A1 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2007-10-18 | — | — | US | disclosed |
| US-20060154988-A1 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244197-A1 | Antibacterial agents | MRPL21, SI, PGLS | MCHR1 4181/4885CHRM4 4821/4885CYP2D6 36/4885 |
| US-20080269221-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, PGLS | MCHR1 4181/4885CHRM4 4821/4885CYP2D6 36/4885 |
| US-20060154988-A1 | Antibacterial agents | MRPL21, SI, PGLS | MCHR1 4181/4885CHRM4 4821/4885CYP2D6 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.